• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Haemophilus Infections - Pipeline Review, H2 2012 Product Image

Haemophilus Infections - Pipeline Review, H2 2012

  • ID: 2245106
  • September 2012
  • 75 pages
  • Global Markets Direct

Haemophilus Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Haemophilus Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Haemophilus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Haemophilus Infections. Haemophilus Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Haemophilus Infections.
- A review of the Haemophilus Infections products under development by companies READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Haemophilus Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Haemophilus Infections 9
Haemophilus Infections Therapeutics under Development by Companies 11
Haemophilus Infections Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Haemophilus Infections Therapeutics – Products under Development by Companies 18
Haemophilus Infections Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Haemophilus Infections Therapeutics Development 20
Sanofi-Aventis 20
GlaxoSmithKline plc 21
Merck & Co., Inc. 22
Takeda Pharmaceutical Company Limited 23
Biological E. Limited 24
Wockhardt Limited 25
LG Life Sciences, Ltd 26
Panacea Biotec Limited 27
Evolva SA 28
Sinovac Biotech Ltd. 29
Haemophilus Infections – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
Hib Vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
GSK-2189242A - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Act-HIB® reconstituted with TRIPACEL® - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Menitorix + Priorix - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
GSK-217744 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DTP-HepB-Polio-Hib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
TAK-816 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
DTP-HepB/Hib Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
GSK2189242A + GSK1024850A - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
V419 + Prevnar 13 + RotaTeq - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 50
NU-300 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Hexaxim - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Pentavalent DTwP-HepB-Hib Vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Easysix - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Group A, C Polysaccharide Meningococcal + Type b Haemophilus Influenzal Conjugate Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Second Generation Ketolides - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
EV-035 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GSK-2838500A - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GSK-2838497A - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GSK-2838501A - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Haemophilus Infections Therapeutics – Drug Profile Updates 63
Haemophilus Infections Therapeutics – Discontinued Products 66
Haemophilus Infections Therapeutics - Dormant Products 67
Haemophilus Infections – Product Development Milestones 68
Featured News & Press Releases 68
Jun 22, 2012: Sanofi Pasteur’s Hexaxim Receives Positive Opinion From European Medicines Agency 68
Dec 19, 2011: Viscogel Announces Publication Of Preclinical Results Of ViscoGel 69
Jun 15, 2011: Takeda To Initiate TAK-816 Phase III Clinical Trial In Japan 69
Apr 06, 2011: Nuron Biotech Acquires Assets Related to HibTITER Conjugate Vaccine 70
Jul 30, 2010: Sanofi Pasteur to acquire all shares of Joint Venture with Daiichi-Sankyo in Japan 70
Nov 10, 2008: Sanofi Pasteur First International Vaccine Company to Enter Japan with Pediatric vaccine 71
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 71
Sep 27, 1996: FDA approval of a Haemophilus b Conjugate Vaccine combined by reconstitution with an acellular pertussis vaccine 72
Jun 24, 1996: Connaught applies to FDA for licensing of first acellular pertussis vaccine to be used in combination with hib vaccine for infants 72
Apr 23, 1993: Sanofi Receives FDA Approval For New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine ActHIB for Infants and Children 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Tables
Number of Products Under Development for Haemophilus Infections, H2 2012 9
Products under Development for Haemophilus Infections – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Sanofi-Aventis, H2 2012 20
GlaxoSmithKline plc, H2 2012 21
Merck & Co., Inc., H2 2012 22
Takeda Pharmaceutical Company Limited, H2 2012 23
Biological E. Limited, H2 2012 24
Wockhardt Limited, H2 2012 25
LG Life Sciences, Ltd, H2 2012 26
Panacea Biotec Limited, H2 2012 27
Evolva SA, H2 2012 28
Sinovac Biotech Ltd., H2 2012 29
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 35
Haemophilus Infections Therapeutics – Drug Profile Updates 63
Haemophilus Infections Therapeutics – Discontinued Products 66
Haemophilus Infections Therapeutics – Dormant Products 67

List of Figures
Number of Products under Development for Haemophilus Infections, H2 2012 9
Products under Development for Haemophilus Infections – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Route of Administration, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Molecule Type, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 35

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos